Chinook Therapeutics, Inc. (KDNY)
Price:
40.39 USD
( + 0.09 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
NEWS
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-18 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Novartis Completes Acquisition of Chinook Therapeutics
globenewswire.com
2023-08-11 11:30:00Basel, August 11, 2023 — Novartis today announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-05 07:00:00LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ: KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-04 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-03 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)
gurufocus.com
2023-08-02 12:01:36On August 1, 2023, Andrew King, the Chief Scientific Officer of Chinook Therapeutics Inc ( KDNY , Financial), sold 1,168 shares of the company. This move is part of a series of insider transactions that have taken place over the past year.
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-02 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-01 04:00:00LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-31 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
globenewswire.com
2023-07-28 08:00:00SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
accesswire.com
2023-07-25 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY
businesswire.com
2023-07-21 18:12:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chinook Therapeutics, Inc. (NasdaqGS: KDNY) to Novartis AG. Under the terms of the proposed transaction, shareholders of Chinook will receive $40.00 in cash as well as contingent value rights providing for payment of up to $4.00 per share upon the achievement of certain future regulatory milestones with respec.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-21 04:00:00LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-19 16:30:00LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY
prnewswire.com
2023-07-17 18:03:00NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such investors are advised to contact Robert S.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
No data to display
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-18 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Novartis Completes Acquisition of Chinook Therapeutics
globenewswire.com
2023-08-11 11:30:00Basel, August 11, 2023 — Novartis today announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-05 07:00:00LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ: KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-04 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-03 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)
gurufocus.com
2023-08-02 12:01:36On August 1, 2023, Andrew King, the Chief Scientific Officer of Chinook Therapeutics Inc ( KDNY , Financial), sold 1,168 shares of the company. This move is part of a series of insider transactions that have taken place over the past year.
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-02 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-01 04:00:00LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-31 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
globenewswire.com
2023-07-28 08:00:00SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
accesswire.com
2023-07-25 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY
businesswire.com
2023-07-21 18:12:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chinook Therapeutics, Inc. (NasdaqGS: KDNY) to Novartis AG. Under the terms of the proposed transaction, shareholders of Chinook will receive $40.00 in cash as well as contingent value rights providing for payment of up to $4.00 per share upon the achievement of certain future regulatory milestones with respec.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-21 04:00:00LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-19 16:30:00LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY
prnewswire.com
2023-07-17 18:03:00NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such investors are advised to contact Robert S.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.